NIH R01 · 2024
ABSTRACT Most patients with pulmonary arterial hypertension (PAH) die from right ventricular (RV) failure and all experience exercise limitation. No RV-specific therapies exist because the mechanisms underlying RV failure are poorly understood. The discovery of novel, potentially treatable causes of RV failure and exercise limitation would be an important advance in the treatment of PAH. RV steatosis may be a novel mechanism of RV failure in human PAH. We and others reported a high prevalence of insulin resistance in patients with PAH. We recently published that insulin resistance in PAH manifests primarily as abnormalities in lipid metabolism. Patients with PAH had elevated circulating…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.